Mayne Pharma began construction on a new $65-million pharmaceutical manufacturing facility in Greenville, NC. The 126,000-sq.-ft., oral-dose facility will more than double the company’s U.S. manufacturing capacity. Also, the re-purposing of space within the existing facility will significantly expand capacity for contract analytical lab and formulation development services with more than 10 new processing rooms and expanded labs. 
 
The new facility will house commercial manufacturing and packaging operations for Mayne Pharma’s generic and branded drug products. These operations also create new business opportunities for Metrics Contract Services (MCS) clients with expanded downstream commercial manufacturing services.
 
The company can now introduce commercial-scale manufacturing capability using solvent-based, fluid-bed processing technologies for modified-release bead/pellet products — an offering Mayne Pharma provides at its Australia facility. The company has seven modified-release products in the pipeline, three of which have been filed with the FDA.
 
Additionally, the new building has been designed to allow for the safe handling of highly potent products at greater scale. Mayne Pharma currently has four highly potent products in the pipeline. All U.S. distribution will be consolidated to Mayne Pharma’s Greenville campus.
 
“Mayne Pharma will triple its global fluid-bed processing capability once this facility opens, strengthening considerably our leadership position in oral drug delivery,” said Stefan Cross, president of Mayne Pharma USA. “The company will have greater flexibility to expand its modified-release product portfolio and support key existing product franchises that include
Doxycycline, Morphine Sulfate and Erythromycin.”
 
The company anticipates that the new commercial facility should be fully operational in 2018, and expects to hire 110 new scientists, quality assurance specialists and other technicians to support expanded operations.